Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia

Autor: Pieters R, Gj, Kaspers, Er, Wering, Dr, Huismans, Ah, Loonen, Hählen K, Anjo JP Veerman

Publikováno v: Europe PubMed Central

Immunophenotype and age have prognostic value in childhood acute lymphoblastic leukemia (ALL) but how this operates is not understood. In 84 children with ALL at initial diagnosis we studied the correlation between these factors and the in vitro resi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::67d73d438f3b9132b124f68fec77f574
https://pubmed.ncbi.nlm.nih.gov/8445945

Adenosine deaminase and purine nucleoside phosphorylase in childhood lymphoblastic leukemia: relation with differentiation stage, in vitro drug resistance and clinical prognosis

Autor: Pieters R, Dr, Huismans, Ah, Loonen, Gj, Peters, Hählen K, van der Does-van den Berg A, Er, Wering, Anjo JP Veerman

Publikováno v: Europe PubMed Central

Many reports have described the relationship of adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP) activities with the immunological subclasses of acute lymphoblastic leukemia (ALL). The clinical significance of these enzymes in leuk

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::29fdd3f803736d98256770d15686dc47
http://europepmc.org/abstract/med/1593902

Challenging diagnosis in a patient with clear lymphoid immunohistochemical features and myeloid morphology: mixed phenotype acute leukemia with erythrophagocytosis.

Autor: de Leeuw DC; Department of Hematology, CCA-V-ICI, VU University Medical Center, Amsterdam, The Netherlands. d.deleeuw@vumc.nl, van den Ancker W, Westers TM, Loonen AH, Bhola SL, Ossenkoppele GJ, van de Loosdrecht AA

Publikováno v: Leukemia research [Leuk Res] 2011 May; Vol. 35 (5), pp. 693-6. Date of Electronic Publication: 2011 Feb 21.

Large interindividual differences in cellular sensitivity to calicheamicin may influence gemtuzumab ozogamicin response in acute myeloid leukemia.

Autor: Goemans BF, Zwaan CM, Vijverberg SJ, Loonen AH, Creutzig U, Hählen K, Reinhardt D, Gibson BE, Cloos J, Kaspers GJ

Publikováno v: Leukemia [Leukemia] 2008 Dec; Vol. 22 (12), pp. 2284-5. Date of Electronic Publication: 2008 Jun 19.

Incidence of additional genetic changes in the TEL and AML1 genes in DCOG and COALL-treated t(12;21)-positive pediatric ALL, and their relation with drug sensitivity and clinical outcome.

Autor: Stams WA; Erasmus MC, Sophia Children's Hospital, Erasmus University Medical Center Rotterdam, Division of Pediatric Oncology/Hematology, Rotterdam, The Netherlands., Beverloo HB, den Boer ML, de Menezes RX, Stigter RL, van Drunen E, Ramakers-van-Woerden NL, Loonen AH, van Wering ER, Janka-Schaub GE, Pieters R

Publikováno v: Leukemia [Leukemia] 2006 Mar; Vol. 20 (3), pp. 410-6.